FDA Accepts Supplement Application for COLUMVI (BLA761309) by Genentech
The FDA has accepted a supplemental biologics license application (BLA) for COLUMVI (glofitamab-gxbm) submitted by Genentech.
Therapeutic Area
Therapeutic area intelligence for Bispecific T-cell Engager with 7 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
The FDA has accepted a supplemental biologics license application for TECVAYLI (teclistamab-cqy), indicating ongoing development.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.